KAYTUS
21.5.2024 12:18:30 CEST | Business Wire | Press release
KAYTUS, a leading IT infrastructure provider, introduced at ISC High Performance 2024 its high-density computing server KR1280V2. It supports 32 E1.S SSDs, achieving an impressive flash memory density of 512TB in a 1U form factor. Compared to the last generation, KR1280V2 adopts low latency storage and network design, doubling the high concurrency I/O performance for LLM training scenarios, and improving model training efficiency.
This 1U2S flagship server is powered by the latest Intel, AMD, or ARM processors. The KR1280V2 features an optimized cooling strategy to support CPUs with the highest TDP across platforms, without configuration restrictions. It also introduces a novel front I/O configuration, enhancing scalability with 8 PCIe 5.0 expansion cards and improving maintenance efficiency in data centers. The server’s drive tray type has been optimized to offer an innovative storage configuration of 12 front SFF drives, increasing storage density by 20%.
Supports 32 E1.S SSDs without performance degradation, delivering tens of millions IOPS
Powered by 5th Gen Intel® Xeon® processors and boasting remarkable computing density, the KR1280V2 supports up to 32 all-flash E1.S SSDs directly connected to CPUs within a 1U form factor. This configuration harnesses the full I/O rate of PCIe 5.0, maximizing throughput between CPUs and storage, achieving up to 160GB/s storage throughput. With load balancing across two OCP 3.0 cards, it doubles network bandwidth, catering to diverse data storage and processing needs while enhancing overall computing performance by 60%.
With ultimate flash memory density, the KR1280V2 effectively doubles LLMs' high concurrency performance
The KR1280V2 achieves tens of millions of IOPS performance in distributed storage scenarios, marking a remarkable 77% improvement. Deploying KR1280V2 servers for large-scale LLMs training ensures a twofold increase in high-concurrency I/O performance compared to the previous generation. As the number of GPUs and workload increases, the KR1280V2's latency curve becomes smoother and more predictable, demonstrating a notable 13% improvement in data latency also compared to the prior generation. These significant advancements enhance data preparation efficiency, model training, and data management while reducing wasted storage space. Consequently, it delivers robust storage capacity and performance for innovative LLM applications and better supports Java-based business scenarios requiring massive data, low latency, and high concurrency, such as in finance, cloud services, enterprises, and other data center applications.
Optimized cooling technologies and exceptional business reliability and sustainability
In terms of heat dissipation, the KR1280V2 supports multiple cooling methods, including EVAC heatsink air cooling, cold-plated liquid cooling, and single-phase immersion liquid cooling. It achieves an 8% to 12% power reduction through fan partition regulation, one-click BIOS optimization, and other techniques across 17 energy-efficient scenarios. Additionally, the KR1280V2 employs numerous advanced technologies to enhance stability and security. It introduces the exceptional MUPR2.0 early detection memory fault function, which utilizes a more comprehensive memory scrubbing technique to self-check and fix memory faults, achieving a broader range of error correction and a higher level of system protection. Consequently, the system's downtime rate is 69% lower than the industry average.
To learn more about the KAYTUS KR1280V2 high-density server, please visit the website.
About KAYTUS
KAYTUS is a leading provider of IT infrastructure solutions, delivering a diverse range of cutting-edge, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521588996/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom